Wearable and Flexible Electrochemical Sensors for Sweat Analysis: a Review
7 Articles
7 Articles
Wearable and flexible electrochemical sensors for sweat analysis: a review
Flexible wearable sweat sensors allow continuous, real-time, noninvasive detection of sweat analytes, provide insight into human physiology at the molecular level, and have received significant attention for their promising applications in personalized health monitoring. Electrochemical sensors are the best choice for wearable sweat sensors due to their high performance, low cost, miniaturization, and wide applicability. Recent developments in s…
Chinese scientists develop wearable sweat sensing system for early Parkinson's disease warning
A research team led by Zhang Qiang with the Changchun Institute of Applied Chemistry under the Chinese Academy of Sciences has developed a fully integrated wearable sweat sensing patch for online analysis of multiple Parkinson's disease-related biomarkers.The
Photo by depositphotos.com Changchun.- A research team led by Zhang Qiang, of the Changchun Institute of Applied Chemistry, a subsidiary of the Chinese Academy of Sciences, has successfully developed a fully integrated portable sweat detection patch for online analysis of multiple biomarkers related to Parkinson’s disease. The research was published on Tuesday (Beijing time) in the international magazine “Advanced Materials”. According to this s…
Casma to develop CSM-101 as treatment for Parkinson's
Casma Therapeutics said it will develop CSM-101 as a potential disease-modifying oral treatment for people with Parkinson’s disease and Gaucher disease. CSM-101 is a first-in-class small molecule designed to activate the calcium channel TRPML1, a key regulator of lysosomal function and autophagy, a process in which cells deliver waste to cellular structures called lysosomes to be broken down and recycled. Boosting autophagy is aimed at reducing …
Casma selects treatment CSM-101 for Gaucher-related Parkinson's
Casma Therapeutics has selected its first experimental therapy candidate, dubbed CSM-101, which will be developed to treat Gaucher’s disease patients who have Parkinson’s disease. The company is planning to submit an investigational new drug application to the U.S. Food and Drug Administration (FDA) in 2026 asking for permission to start clinical testing in people. “Our nomination of CSM-101 marks a major milestone for Casma and the field as we …
Coverage Details
Bias Distribution
- 75% of the sources lean Left
To view factuality data please Upgrade to Premium